Core Viewpoint - The strategic partnership between Huaxi Bio and LG Household & Health Care focuses on synthetic biology technology to address skin aging and develop innovative solutions for the beauty industry [2][9]. Group 1: Partnership Details - Huaxi Bio and LG Household & Health Care signed a Memorandum of Understanding (MOU) on September 22, 2025, in Seoul, aiming to tackle skin aging through collaborative research [2]. - The partnership emphasizes the shift in the beauty industry from merely improving wrinkles to a new focus on "skin longevity," which aims to extend the healthy lifecycle of skin [2]. Group 2: Company Strengths - Huaxi Bio leverages its leading synthetic biology and biomanufacturing platform, along with advanced pilot conversion facilities, to develop bioactive substances closely related to human health [4]. - The company maintains a global leading position in hyaluronic acid while actively expanding into areas such as glycoscience, cell biology, and regenerative medicine for anti-aging technologies [4]. Group 3: LG Household & Health Care Innovations - LG Household & Health Care is recognized for its strong research capabilities in the beauty sector, focusing on cellular-level anti-aging and the efficacy of wild ginseng [6]. - The company has introduced innovative anti-aging research outcomes, such as NAD Power24, integrating cutting-edge research into high-end skincare products [6]. Group 4: Future Outlook - The collaboration aims to develop competitive innovative products that provide effective anti-aging solutions for global consumers [9]. - Both companies believe that combining their expertise will lead to groundbreaking anti-aging products for the global market [9].

Core Insights - The company, Xiangyi Bencao, highlighted the challenges in modernizing and scientific validation of traditional Chinese herbal medicine during the 2025 China Fragrance and Cosmetic Industry Annual Conference [1][3] - The external challenges include intense market competition and a growing focus on effective ingredients, necessitating differentiation in the herbal product offerings [1][3] - Internally, the company faces challenges in product planning, balancing the use of traditional herbal ingredients with modern scientific components [3] External Challenges - The market environment is highly competitive, with consumers increasingly focused on effective ingredients such as niacinamide, leading to a need for differentiation in herbal products [1] - The emphasis on understanding the mechanisms and targets of herbal ingredients poses a challenge for the company in standing out in the crowded market [1] Internal Challenges - Product planning involves deciding between combinations of traditional herbal ingredients or integrating them with modern scientific components, requiring clear strategic alignment [3] - The technical difficulties in understanding the mechanisms, extraction processes, and formulation of herbal ingredients complicate product development [3] Differentiation and Competitive Advantage - Xiangyi Bencao has committed to a long-term strategy focused on traditional herbal medicine, facing numerous challenges in this path [3] - The brand's differentiation lies in its core product lines, utilizing key active ingredients like Rhodiola, Camellia, and Gentian, and exploring synergistic effects between different plants [3] - The company draws inspiration from traditional remedies and verified formulas, translating them into innovative products [3] Technological Integration - The company employs AI-driven precision development, leveraging nearly 20 years of research on Rhodiola to enhance the R&D process from raw materials to formulation [3] - AI technology significantly improves efficiency in matching ingredients with efficacy mechanisms, streamlining the experimental validation process [3][4] - Future R&D will focus on deep exploration of herbal materials and the integration of AI in plant research, alongside interests in synthetic biology and biopharmaceuticals [4]

Core Insights - The discussion at the 2025 Pujiang Innovation Forum highlighted the core challenges and breakthrough strategies in the field of synthetic biology, which is seen as a disruptive field with a broad future [2][3] Challenges and Breakthroughs - The main challenge in synthetic biology is the complexity and uncertainty of biological systems, which requires an engineering approach to design life [3] - Key issues include stability during scaling processes, energy consumption of cell factories, and the lack of predictive design tools [3] - Current advancements in biological development processes, such as using engineered yeast in traditional industrial platforms, face fundamental challenges in strain engineering and construction models [3] - The need to address stability issues during strain expansion immediately rather than waiting until scaling is crucial for successful engineering [3] Perspectives on Scaling - The perception that scaling challenges in synthetic biology are exaggerated is noted, with emphasis on the high costs associated with scaling processes [4] - Solutions should focus on optimizing laboratory conditions to ensure that microbial performance in lab settings translates to scaled production [4] - The comparison of costs between synthetic biology and chemical products should be made on a fair basis, considering sustainability and environmental benefits [4] Global Collaboration and Market Entry - Collaboration between global synthetic biology technologies and Chinese factories is essential for achieving scalable progress [5] - China's stable policy environment, reliable competition, and the technical background of policymakers contribute to a favorable landscape for synthetic biology projects [5] - Scientists must have a long-term vision when commercializing disruptive technologies, considering distribution and sales alongside product development [6] Future Outlook - Synthetic biology is expected to make specialty chemicals more accessible and competitively priced, with localized production becoming more feasible [6][7] - The potential of synthetic biology in regenerative medicine is significant, offering solutions for chronic diseases and promoting healthier lifestyles through preventive measures [7]

Core Insights - Liu Xiuyun, a rising academic star, returned to Tianjin University to teach after studying at prestigious institutions, embodying the university's spirit of "self-improvement" and national service [1][2] - Tianjin University, celebrating its 130th anniversary, showcases significant breakthroughs in various fields, including brain-computer interface technology and new energy chemical catalysis [1][3] - The university emphasizes the importance of aligning research with national needs, fostering a culture of practical and impactful scientific inquiry [3][5] Group 1: Academic Contributions - Liu Xiuyun completed her studies and postdoctoral research at top universities in a short time, demonstrating exceptional learning ability [2] - Tianjin University's chemical engineering discipline ranks among the top 0.1% globally, reflecting its historical connection to national development [3] - The university's faculty and students are actively engaged in research that addresses real-world industrial challenges, such as the development of new technologies in chemical engineering [3][5] Group 2: Educational Philosophy - The university's motto "seeking truth from facts" has been a guiding principle for over a century, emphasizing practical application in education and research [6][7] - Recent initiatives include the establishment of new academic programs and a focus on interdisciplinary studies to meet the evolving demands of the industry [10][12] - Tianjin University aims to cultivate a new generation of leaders equipped to tackle future challenges, aligning educational outcomes with national strategic needs [10][12] Group 3: Innovation and Industry Collaboration - Faculty members are encouraged to engage in research that directly benefits industry, reflecting a shift in academic evaluation criteria towards practical contributions [4][5] - The university has launched programs targeting emerging fields such as synthetic biology and brain-computer interfaces, aiming to produce competitive talent in these areas [11][12] - Tianjin University is committed to fostering innovation through collaboration with industries, ensuring that research translates into real-world applications [12][13]

Core Viewpoint - The biomanufacturing sector is recognized as a key engine for the new technological revolution and industrial transformation, with Changde aiming to establish itself as a national-level industrial cluster by 2025 [1][4]. Group 1: Industry Development - Changde has nurtured several biopharmaceutical companies, including YunGang Bio and LiEr Bio, with 35 core enterprises in synthetic biomanufacturing expected to achieve a production value exceeding 7.5 billion yuan by mid-2025 [1][4]. - YunGang Bio has developed a GMP-standard automated production line for extracting and synthesizing ursodeoxycholic acid from animal bile, achieving a conversion rate of over 99% and capturing more than one-third of the domestic market for its core product [2][3]. - Changde's synthetic biomanufacturing industry has shown significant growth, with a production value of 7.689 billion yuan as of July 2025, reflecting a year-on-year increase of 23.52% [3]. Group 2: Technological Innovation - The foundation of synthetic biology and biomanufacturing is held by companies like MuEn Bio, which has identified over 320,000 proprietary microbial strains, enabling high-throughput screening for bioactive microorganisms and their metabolites [2][3]. - MuEn Bio has established a comprehensive DREAM technology platform that covers the entire process from resource discovery to product development, enhancing its competitive edge in biomanufacturing [3]. Group 3: Ecosystem and Support - Changde is building a comprehensive industrial ecosystem with support from policies, talent acquisition, and financial backing, aiming to accelerate the transition from technological breakthroughs to large-scale implementation [4][5]. - The establishment of a 5 billion yuan biomanufacturing mother fund and a 1 billion yuan innovation guidance fund is part of Changde's strategy to inject "patient capital" into the biomanufacturing sector [4]. Group 4: Future Prospects - By 2028, Changde aims to achieve a production value of over 30 billion yuan in synthetic biomanufacturing and to cultivate more than 100 enterprises in the sector, including over 50 high-tech companies [6]. - The biomanufacturing industry in China has reached a total scale of nearly 1 trillion yuan, with fermentation capacity accounting for over 70% of the global market, indicating significant growth potential [5][6].

Report Summary 1. Report Industry Investment Rating No information provided in the document. 2. Core Viewpoints - The company is the first in China to successfully put into production a TBS production device. TBS has excellent performance and a wide range of downstream applications, with good market prospects under the trend of industrial upgrading and import substitution [24][37]. - The company attaches great importance to the strategic value and development potential of cutting - edge technology fields such as synthetic biology. The Taizhou project (Phase I) is an extension of the company's product matrix and technology accumulation, aiming to enrich product categories [25][30][32]. - The company's R & D adopts a model of internal R & D combined with university cooperation. The existing R & D team is mainly composed of senior technical backbones with over 10 years of industry experience, which is in line with the current R & D needs of the company [27][28]. - The company's products are mainly high - molecular new material special monomers and special additives, which have the characteristics of small dosage, great effect, and high added value in the downstream high - molecular new material industry system [38]. 3. Summary According to the Directory 3.1 Research Basic Situation - The research object is Changqing Technology. The reception time was on September 26, 2025. The listed company's reception personnel included the chairman and general manager, the director and board secretary, the financial controller, and the independent director [17]. 3.2 Detailed Research Institutions - The research institutions mainly include investors and others [20]. 3.3 Research Institution Proportion No information provided in the document. 3.4 Main Content Information - **Product Application and Market**: TBS has been sent for sampling and sales in multiple industries and is expected to be applied in more industries. The company's products can be used in multiple fields of the big - health industry, such as high - end medical consumables, biomedicine, and food packaging [24][26]. - **Project Planning**: The Taizhou project (Phase I) is an extension of the company's product matrix and technology accumulation. The second - and third - phase plans will be scientifically demonstrated and decided based on the operation results of the first - phase project, market trends, and R & D progress [25][30][35]. - **New Product Promotion and Production Capacity**: Some new products of the company's fund - raising projects have been sent to customers for sampling or obtained orders, and the production capacity and benefits are gradually being released. The seventh - phase project is in the trial - production stage [27][31][41]. - **R & D and Technology**: The company's R & D adopts a combination of internal R & D and university cooperation. The company's unique technology path is difficult to be imitated by competitors, and the company attaches great importance to technology confidentiality [27][28][34]. - **Market and Sales**: The company's products are sold overseas, with an export proportion of about 35% during the reporting period, mainly to Europe, Japan, South Korea, Southeast Asia and other countries or regions [24][33][37]. - **Production Capacity and Performance**: The company's production capacity is in a stable and rising trend. The production capacity of the fund - raising project is gradually climbing. Regarding the third - quarter performance, please refer to the company's subsequent regular reports [41].

Core Insights - A new dual-mode CRISPRa/i gene editing system has been developed by South Korean scientists, allowing simultaneous "activation" and "suppression" of different genes, overcoming the limitations of existing CRISPR technology which primarily focuses on gene suppression [1][2]. Group 1: Technology Development - The new system was developed through collaboration between the Korea Advanced Institute of Science and Technology and the Korea Institute of Chemical Technology [1]. - The dual-mode gene scissors enable precise control of gene expression, akin to an electrical switch, which is crucial for optimizing metabolic pathways in synthetic biology [1][2]. Group 2: Performance Metrics - In experiments, the new system demonstrated significant performance improvements: protein expression levels increased by 4.9 times during activation experiments, while protein production decreased by 83% during suppression experiments [2]. - The system successfully achieved simultaneous regulation of two genes, with one gene's activity increased by 8.6 times and the other gene suppressed by 90% [2]. Group 3: Industry Implications - This dual-mode CRISPR system is expected to provide powerful tools for metabolic pathway optimization, gene network research, and bacterial functional genomics, potentially enhancing the efficient production of high-value compounds, biofuels, and pharmaceuticals [2].

点击 最 下方 "在看"和" "并分享，"关注"材料汇 添加 小编微信 ，遇见 志同道合 的你 正文 一. 先进制造:行业图谱与成长逻辑 1. 新一轮科技革命和产业变革加速:聚焦先进制造 中国制造业的地位:规模和增速全球领先 ● 统计数据显示:我国制造业的总产出规模、产出增速和GDP占比在全球主要国家中第一 中国:在2020-2023年的三年,制造业复合年均增速约是5. 4%; 美国:在2020-2022年的两年,制造业年均复合增速约是5.0%,数据亦全线回升。 中美日GDP制造业规模 中美日GDP结构占比:制造业 GDP:第二产业 三社川源: 名 一起思想观看他一 建筑业 GDP:制造业(右轴) 30.09 35.0 200.0 180.0 25.0% 30.0 160.0 03 6 25.0 20.0% 140.0 万亿人民币 120.0 20.0 15.0% 100.0 8% 10. 1% 10. 15.0 80.0 10.09 60.0 10.0 6.4 5.0% 40.0 5.0 20.0 0.0% 0.0 0.0 2017 2020 2023 2020 2017 2020 2022 2017 20 ...

Core Insights - The article discusses significant advancements made by Professor Deng Yu's research team at Jiangnan University in the design and strength regulation of Escherichia coli core promoters, published in Nucleic Acids Research [1][5] - The research addresses the challenges in accurately predicting and rationally designing bacterial core promoters, which are crucial for transcription initiation [1][2] Research Progress - The team developed a comprehensive platform that integrates rational library construction, predictive modeling, and generative design to achieve programmable regulation of E. coli core promoters [2][3] - They introduced the Mutation-Barcoding-Reverse Sequencing (MBRS) strategy, creating a high-quality dataset of 112,955 promoters, covering a 16,226-fold expression range [2][3] Model Performance - A Transformer model trained on this dataset achieved high prediction accuracy with a correlation coefficient of R = 0.87, revealing attention patterns consistent with classical motifs and contextual dependencies [3] - The platform can generate novel promoters with precise target strengths, achieving a correlation coefficient of R = 0.95, and demonstrated good generalization across different genetic backgrounds (R = 0.93) [3] Application and Impact - The designed promoters exhibited stable modular "plug-and-play" regulatory effects in both constitutive and inducible systems, contributing to the optimization of microbial cell factories [3][6] - The research has been supported by various funding sources, including the National Key Research and Development Program and the National Natural Science Foundation [5]

Group 1 - The company currently offers inositol as its vitamin product and plans to launch additional vitamin and amino acid products in the future [1]